Nature Communications

Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial

2025-11-28

Full text

DOI https://doi.org/10.1038/s41467-025-66667-y